IQVIA_Rules_Based_Medicine_Logo - rgb

(+01) 512 835 8026

Email us

Type your search term and press "enter."

Interleukin-6 Simoa

Interleukin-6 Simoa

Interleukin-6 (IL-6) is a secreted proinflammatory protein that is part of the IL-6 cytokine family. IL-6 is produced mainly by monocytes, macrophages, dendritic cells, and T cells, but other cells, such as epithelial cells, endothelial cells, fibroblasts, adipocytes, and keratinocytes, are capable of secreting IL-6 under inflammatory conditions. Several agents can induce IL-6 production, including pathogen-associated molecular patterns (PAMPs) such as toll-like receptor agonists and damage-associated molecular patterns (DAMPs) such as mitochondrial DNA. IL-6 signals through binding of either the membrane bound or soluble IL-6 receptor (mIL-6R, sIL-6) as it complexes and activates gp130. Membrane bound IL-6R expression is restricted to immune cells and hepatocytes. However, since nearly all cells express gp130, trans-signaling of IL-6 through binding to the sIL-6R can occur in any cell. IL-6 promotes induction of other inflammatory cytokines and chemokines and plays a role in recruitment of neutrophils and monocytes, promotion of B cell development, regulation of liver metabolism, and stimulation of tumor cell proliferation, survival and invasiveness. In addition, IL-6, in combination with TGF-a, induces development of TH17) cells and production of IL-17.

Swiss-Prot Accession Number: P05231


Bibliography

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena (2022) Anita Borski, Farsad Eskandary, Susanne Haindl, Konstantin Doberer, Jakob M?hlbacher, Katharina A Mayer, Klemens Budde, Philip F Halloran, Edward Chong, Bernd Jilma, Georg A B?hmig, Markus Wahrmann Transplantation

medical_services Therapy Indications

Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism (2021) Muhlbacher J, Schorgenhofer C, Doberer K, Durr M, Budde K, Eskandary F, Mayer KA, Schranza S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Bohmig GA Transplant Internatinoal

medical_services Therapy Indications

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). (2020) Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C,, Rae J, Toth B, Ramamoorthi N, Hackney JA, Berman A, Damjanov N, Fedkov D, Jeka S, Chinn W, Townsend MJ, Morimoto AM, Genovese MC Arthritis& Rheumatology

medical_services Therapy Indications